Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Current Quarter	$-0.09	Next Quarter	$-0.1
Current Year	$-0.37	Next Year	$-0.33
QoQ Growth	-11.1%	YoY Growth	+10.8%
3Y EPS CAGR	N/A	Target Price	$11.00
Consensus	Buy	Upside	+289.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GALT	$2.83	+1.99%	336.75K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GALT	$2.83	+2.0%	336.75K
3
4
5
6

GALT

GALT

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Galectin Therapeutics Inc. Data in Excel

Get Galectin Therapeutics Inc. Data in Excel